s48168
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2019 (NCT04141670)
Timeline
Indications
Mechanism of action
- FK506-binding protein 1ASTABILISER
FKBP1A stabiliser
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05122975 | Phase 2 | Dec 31, 2021 | Armgo Pharma, Inc., Mayo Clinic |
| NCT04141670 | Phase 1 | Oct 30, 2019 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Armgo Pharma, Inc. | For profit | 1 | 1 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1